Cambridge Investment Research Advisors
CPRX

Cambridge Investment Research Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Buy
10,203
+442
+5% +$13K ﹤0.01% 3145
2026
Q1 		$242K Sell
9,761
-1,700
-15% -$40.5K ﹤0.01% 3487
2025
Q4 		$267K Buy
11,461
+676
+6% +$15.1K ﹤0.01% 3315
2025
Q3 		$212K Buy
10,785
+1,170
+12% +$24.1K ﹤0.01% 3435
2025
Q2 		$209K Sell
9,615
-10,353
-52% -$244K ﹤0.01% 3315
2025
Q1 		$484K Buy
+19,968
New +$450K ﹤0.01% 2468
2023
Q1 		– Sell
-21,457
Closed -$399K – 3171
2022
Q4 		$399K Buy
+21,457
New +$330K ﹤0.01% 2201

Other funds holding CPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
CWP
Cyndeo Wealth Partners St. Petersburg, Florida $2.12B AUM 24.61% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CNAM
Campbell Newman Asset Management Milwaukee, Wisconsin $1.35B AUM 38.87% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return

Cambridge Investment Research Advisors's CPRX Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 4.5% in Q2 2026, buying an estimated $13K and bringing the position to 10,203 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #3145.

Cambridge Investment Research Advisors first reported a position in CPRX in Q4 2022 and has held it in 7 quarters since. The position peaked at $484K in Q1 2025. 80 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Cambridge Investment Research Advisors held 10,203 shares of Catalyst Pharmaceutical worth $321K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 442 Catalyst Pharmaceutical shares in Q2 2026, an estimated $13K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3145 holding.
  • Cambridge Investment Research Advisors first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 7 quarters since.
  • Cambridge Investment Research Advisors's Catalyst Pharmaceutical position peaked at $484K in Q1 2025.
  • 80 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.